𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase III trial of subcutaneous administration of rhG-CSF in the myelodysplastic syndromes

✍ Scribed by Y. Yoshida

Book ID
113239971
Publisher
Elsevier Science
Year
1994
Tongue
English
Weight
184 KB
Volume
18
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Decitabine improves patient outcomes in
Decitabine improves patient outcomes in myelodysplastic syndromes : Results of a phase III randomized study
✍ Hagop Kantarjian; Jean-Pierre J. Issa; Craig S. Rosenfeld; John M. Bennett; Mahe πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 204 KB

## Abstract ## BACKGROUND Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy. Decitabine indirectly depletes methylcytosine and causes hypomethylation of target gene promoters.